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Abstract
Purpose of the Review The SARS-CoV-2 genome has been sequenced and the data is made available in the public domain.
Molecular epidemiological investigators have utilized this information to elucidate the origin, mode of transmission, and contact
tracing of SARS-CoV-2. The present review aims to highlight the recent advancements in the molecular epidemiological studies
along with updating recent advancements in the molecular (nucleic acid based) diagnostics for COVID-19, the disease caused by
SARS-CoV-2.
Recent Findings Epidemiological studies with the integration of molecular genetics principles and tools are now mainly focused
on the elucidation of molecular pathology of COVID-19. Molecular epidemiological studies have discovered the mutability of
SARS-CoV-2 which is of utmost importance for the development of therapeutics and vaccines for COVID-19. The whole world
is now participating in the race for development of better and rapid diagnostics and therapeutics for COVID-19. Several
molecular diagnostic techniques have been developed for accurate and precise diagnosis of COVID-19.
Summary Novel genomic techniques have helped in the understanding of the disease pathology, origin, and spread of COVID-
19. The whole genome sequence established in the initial days of the outbreak has enabled to identify the virus taxonomy. Several
rapid, accurate, and sensitive diagnostic methods have been developed; those are based on the principle of detecting SARS-CoV-
2 nucleic acids in clinical samples. Most of these molecular diagnostics are based on RT-PCR principle.
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Introduction
The Coronavirus Disease 2019 (COVID-19) pandemic be-
came a global concern within a few months of the first report
of the disease in December, 2019 in Wuhan, China. Soon,
COVID-19, the zoonotic disease caused by the Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus,
became the major focus in almost all the fields of biological
sciences. Scientists and researches all over the globe started
investigating the molecular pathogenesis of the disease. The
major disciplines of biological sciences such as molecular
genomics, virology, and especially the molecular epidemio-
logical discipline have been affected widely [1–3]. Several
diagnostic methods have been developed as a result of the
investigation and elucidation of the genomic sequence of the
SARS-CoV-2 and the knowledge about its evolutionary his-
tory. The present review summarizes the molecular epidemi-
ological studies related to COVID-19 and the recent advance-
ments in the development of molecular diagnostics for
COVID-19.
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Molecular Epidemiology of COVID-19
The International Association of Epidemiology defines mo-
lecular epidemiology as “the application of epidemiologic
principles to study the molecular, biochemical, cellular and
genetic mechanisms that underlie the pathophysiology, etiol-
ogy and prevention of human diseases and related outcomes,
as well as their early detection, treatment, or prognosis”.
The application of systems biology, genomics, molecular,
and cell biology techniques in epidemiology discipline has
revolutionized the field of epidemiology and this has given a
new discipline altogether calledmolecular epidemiology. This
integrated multidisciplinary approach has resulted in the dis-
covery of several novel biomarkers (genomic) to trace various
infectious diseases. Also, molecular epidemiological studies
have explored the etiology of several diseases providing de-
tailed knowledge about the molecular pathology and disease
progression. Ultimately, these contributions of the molecular
epidemiological studies help design preventive strategies and
management protocols [4]. Rapid advancements in sequenc-
ing technologies have further advanced the field of molecular
epidemiology. The traditional molecular techniques have been
made high throughput with these advancements. Therefore,
these high throughput molecular sequencing-based technolo-
gies have started replacing the traditional molecular diagnos-
tics and this has made the epidemiological investigations of
the infectious diseases more rapid, specific, and sensitive.
Sequencing and analysis of the whole genomic sequence of
the pathogens in comparison with the already available data-
base of sequences can increase the speed and accuracy of the
epidemiological studies, thereby helping in the investigations
of the disease pathogenesis and ways to tackle the infectious
diseases [5].
Novel genomic techniques have helped in the understand-
ing of the disease pathology, origin, and spread of COVID-19.
The whole genome sequence established in the initial days of
the outbreak has enabled to identify the virus taxonomy.
These molecular tools have established that SARS-CoV-2 be-
longs to betacoronavirus family and shows clear divergence
from SARS-CoV and MERS-CoV [6–8]. Application of a
combination of genomic tools and phylogenetic analysis
methods revealed that the SARS-CoV-2 along with the Bat-
SARS-like coronavirus cluster together into a discrete lineage
and the subgenus, Sarbecovirus [9, 10••].
The virology field has integrated the next-generation se-
quencing tools and has now moved from targeted sequencing
of single genomes to genomic epidemiology [11]. These ad-
vancements have enabled the parallel sequencing of thou-
sands of genomic sequences of pathogens of different species
for the detection of pathogens. This approach has resulted in
the availability of more than 2220 full genomes in the SARS-
CoV-2 public database of the Global Initiative on Sharing All
Influenza Data (GISAID) [12]. Initially, GISAID was
dedicated to sharing of genomic data on influenza. However,
GISAID has now extended its scope and has included the
constantly updating SARS-CoV-2 database [13].
The SARS-CoV-2 genomic sequences available till date
mainly fall into three clades. The S clade has 541 genomes,
G clade has 931 genomes, and V clade has 208 genomes.
Other 548 SARS-CoV-2 genomes fall in other additional
clades. Till March 28, 2020, the GISAID repository on recep-
tor binding surveillance has identified four different rare var-
iants in the close proximity of the binding interface. The ge-
nomic variant V483Awas identified in 16 samples fromUSA/
WA, L455I and F456V in one sample from Brazilian sample,
and the genomic variant G476S in 10 samples from USA/WA
samples [12]. The GISAID has also provided potential drug
targets by analyzing the degree of sequence similarity of high-
ly conserved genomic sequences between hCoV-19 and
SARS virus. The main SARS protease shares 96% sequence
identity and the polymerase shows 97% sequence identity
with the protease and polymerase of hCoV-19, respectively.
The inhibitors developed against SARS-CoV protease and
polymerase also bind to the protease and polymerase of
hCoV-19 in a similar way [12].
The evolution in the field of genomics has a prominent
impact on the approaches employed in the epidemiology and
public health [14–16]. Genomic epidemiology has helped re-
construct the evolutionary lineage of the viruses including the
appearance of the viruses and their global spread. This inte-
grated approach has assisted in the exploration of the evolu-
tionary history and the structure and spread of the SARS-
CoV-2 virus. Since the SARS-CoV-2 genome is mutating
constantly, it is important to establish these emerging genomic
variants that would help in understanding the source of trans-
mission and would also help in accessing the community
transmission. Genomic comparisons of the viral genomes help
in tracing the most probable ancestor and from it has originally
originated (the geographic location).
With the emerging numbers of new genomic se-
quences of SARS-CoV-2 from different sources of dif-
ferent geographical locations, a better understanding of
the genomic epidemiology of SARS-CoV-2 would be
established soon. Genomic epidemiology has the potential to
recognize the cluster of transmission, the biological rate of
transmission, and to predict the extent of spread of the
COVID-19 pandemic.
Different countries all over the world have started projects
to identify new genomic sequences of the SARS-CoV-2 virus
to have a tight watch on the progress of the pandemic in terms
of understanding the genetic diversity of the novel virus, the
epidemiological patterns, developing suitable diagnostic pro-
tocols and methods, and ultimately designing of vaccines and
the development of therapeutics for COVID-19. Many coun-
tries from the developed nations such as Europe and North
America have reported genomic sequence of SARS-CoV-2
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isolated from their regions. However, several countries in
Asia, Middle East, Africa, and Latin America lack such infra-
structure and projects. In this case, a number of publically
available open-access platforms such as GISAID and associ-
ated sources (https://nextstrain.org/ncov) have proven to be
useful and easily accessible tools to understand the COVID-
19 pandemic by using the available genomic sequence of the
SARS-CoV-2 virus [12].
Advancements in the Molecular Diagnostics
for COVID-19
Since the day of the availability of the genomic sequence of
SARS-CoV-2 virus in the GISAID, several companies and
research organizations developed several diagnostic molecu-
lar diagnostic methods to detect the SARS-CoV-2 in the clin-
ical samples. The access to the genome sequence data of
SARS-CoV-2 virus has enabled to design primers and probes




RT-PCR is considered to be the gold standard for the detection
of SARS-CoV-2 in the clinical samples. It relies on the
amplification of the viral RNA which is first concerted
to CDNA and then specific primers directed against the
viral genome identify the presence of the virus in the
clinical samples. Samples collected from the upper re-
spiratory tract are currently used for RT-PCR-based test-
ing. Reports are available that highlight the use of se-
rum, stool, and ocular secretions as the source of viral
RNA [18–20]. Most recently self-collected saliva samples
have been used for RT-PCR tests. This method reduces the
pain, risk of infection of the health care providers, and a fast
process [21, 22].
In RT-PCR, the primers target specific sequences on the
viral CDNA and amplify the viral genome. Then, the RT-PCR
is monitored in real time by the use of fluorescent dye or a
sequence-specific DNA probe labeled with a fluorescent mol-
ecule [23].
Different RT-PCR kits target different genomic sequences
of the virus such as ORF1b or ORF8 regions, nucleocapsid
(N), spike (S) protein, RNA-dependent RNA polymerase
(RdRP), or envelope (E) genes [24•, 25–32].
RT-PCR-based methods are rapidly evolving. GenMark
Diagnostics has recently developed a RT-PCR-based kit to
rapidly detect SARS-CoV-2 in nasopharyngeal samples. The
ePlex SARS-CoV-2 test employs test cartridges that contain
reagents for magnetic field-based extraction of viral RNA.
The cartridge also has reagents for cDNA amplification and
detection of viral genome in the sample by the use of
ferrocene-labeled signal probes. The target is detected using
voltammetry [33].
Although RT-PCR is considered as the gold standard for
SARS-CoV-2 detection, it is associated with a few disadvan-
tages. Concerns such as requirement of expensive instru-
ments, highly trained persons, and the time taken to generate
the results have instigated the companies and the researchers
to further improve RT-PCR-based tests as well as to develop
new technologies to detect SARS-CoV-2.
Isothermal Nucleic Acid Amplification
Unlike RT-PCR which requires ramping/changes in tempera-
tures to carry out different steps and requires multiple temper-
ature changes for each cycle, isothermal nucleic acid amplifi-
cation method amplifies viral genomic targets at a constant
temperature. Several methods have been developed based on
this technique.
Reverse Transcription Loop-Mediated Isothermal
Amplification
Reverse transcription loop-mediated isothermal amplification
(RT-LAMP) employs four different primers specific for the
target sequence of the genome and works in combina-
tion with reverse transcription step. Detection is based
on photometry principles that measure the turbidity that
results due to the precipitation of magnesium pyrophos-
phate as a by-product of amplification. This method
allows for real-time monitoring of the results by either
quantifying the turbidity or by fluorescence using fluorescent
dyes. Since RT-LAMP technique needs only heating and vi-
sual monitoring, it is a very simple method and highly sensi-
tive that makes it a potential method for SARS-CoV-2 detec-
tion [34–37].
Transcription-Mediated Amplification
Transcription-mediated amplification (TMA) is based on the
principle of retroviral replication that is used to amplify viral
RNA or DNA targets. Unlike RT-PCR, TMA needs only a
single temperature and is more efficient than RT-PCR [38].
TMA employs a retroviral reverse transcriptase and T7 RNA
polymerase for the detection of several pathogens. Hologic’s
Panther Fusion platform has been developed using the
principles of both RT-PCR and TMA [39]. This is high-
ly sensitive and has very less detection time. It does up to 1000
tests in 24 h and has the capacity to detect other pathogens
whose symptoms overlap with COVID-19 in the same patient
sample.
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Recombinase Polymerase Amplification
Recombinase polymerase amplification (RPA) relies on a
highly sensitive recombinase enzyme that recognizes specific
DNA sequences and then displaces the strands and performs
amplification of virus-specific genes. RPA performs at a sin-
gle temperature and does not need expensive equipments [40].
This method has high potential of testing SARS-CoV-2 in
clinical samples.
CRISPR-Based Assays
Clustered Regularly Interspaced Short Palindromic Repeats
(CRISPR) are a family of nucleic acid sequences present in
prokaryotic organisms like bacteria. Special CRISPR en-
zymes such as Cas9, Cas12, and Cas13 can recognize and
cut these sequences. The Cas12 and Cas13 family of
CRISPR enzymes can be engineered to detect and cleave the
viral RNA sequences [41].
There are two companies (Mammoth Biosciences and
Sherlock Biosciences) that are investigating the possibility
of using this technique in the diagnosis of SARS-CoV-2 virus
in clinical samples. The SHERLOCK method utilizes Cas13
that cuts the reporter RNA sequence upon activated by SARS-
CoV-2-specific guide RNA [42]. The DETECTR assay of the
Mammoth Biosciences utilizes Cas12a that cleaves the report-
er RNA and detects RNA sequences of the E and N genes of
SARS-CoV-2 virus. This is followed by the isothermal ampli-
fication of the target sequences that are monitored visually by
the use of a fluorophore [43]. These methods are sensitive and
specific as well as do not need expensive instruments and can
be developed on a paper strip. These tests take very less time
to generate results as compared with the RT-PCR-based tests
(less than 1 h) [43].
Microarray: Hybridization-Based Assays
Microarray assays are hybridization-based high throughput
methods and have been recently used for the detection of
SARS-CoV-2 nucleic acids in clinical samples. The first step
is to generate cDNA from viral RNA. This is followed by the
labeling of the cDNA with specific probes designed to detect
virus-specific cDNAs in the sample. Then, these labeled
cDNAs are hybridized to complementary oligonucleotide se-
quences on a chip. Then, the signals of the hybridized cDNAs
are quantified by a detector after washing the unhybridized
cDNAs, and hence, the presence of viral nucleic acid is detected
[44]. Recently, the microarray-based methods have been useful
in detecting mutations in the SARS-CoV-2 genome. It has de-
tected 24 single-nucleotide polymorphisms in the SARS-CoV-
2 spike (S) gene with maximum accuracy [45].
The microarray-based techniques are useful in detecting
different strains of SARS-CoV-2 rapidly on a single platform.
However, the biggest drawback of this technique is the asso-
ciated cost. Recently, a low cost and with equal sensitivity to
RT-PCR have been developed to detect SARS-CoV-2 [45].
Amplicon-Based Metagenomic Sequencing
This technique is especially important in genomic epidemio-
logical studies as it simultaneously identifies the SARS-CoV-
2 and the background microbiome that result in secondary
infections. This technique is very useful in contact tracing
and epidemiological studies related to the evolution of the
virus. This is of utmost importance in identifying the muta-
tions acquired by SARS-CoV-2 and in the study of the recom-
bination events that is carried out by the virus with the back-
ground microbiome. This amplicon and metagenomics-based
technique has been used to rapidly sequence the SARS-Co-V-
2 genome in mere 8 h using nasopharyngeal samples from
COVID-19 [46]. The Illumina company has developed ad-
vanced form of this technique where along with detecting
various strains of CoVs, it identifies various other pathogens
in the clinical sample [47].
Conclusion
Epidemiological studies have now integratedmolecular genet-
ics techniques to widen its scope. With the advancements in
the molecular genetics and genomics discipline, sequencing at
single cell level to multiple genomes has become possible. It
has become possible to compare thousands of genomes at one
go with the use of advanced bioinformatics tools. Integrating
these molecule aspects with the epidemiological studies has
given rise to the molecular or genomic epidemiological branch
of science. The molecular epidemiological studies have prov-
en effective in understanding the molecular basis of COVID-
19 along with several other communicable diseases. Rapid
sequencing of the SARS-CoV-2 viral genome has open ave-
nues for the development of anti-virals and vaccines for
COVID-19. The knowledge of the whole genomic sequence
of the SARS-CoV-2 virus has led to the development of sev-
eral molecular diagnostics that target the genomic sequence of
the virus for its detection such as RT-PCR, isothermal ampli-
fication assays, hybridization microarray assays, amplicon-
based metagenomics sequencing, and the cutting-edge
CRISPR-related technologies60. Most of the molecular diag-
nostic tests for COVID-19 are based on RT-PCR. However,
several ramifications to this gold standard technique are under
process and a few have been developed and being used for the
diagnosis of COVID-19. Till date, there are almost 112 mo-
lecular diagnostic tests available to detect SARS-COV-2, and
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of them, 90% of the tests are based on RT-PCR principles,
followed by 6% tests that use isothermal amplification princi-
ples, 2% tests are based on hybridization technologies, and the
rest 2% tests rely on CRISPR-based principles.
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